Breaking News

OBiO, Chinagene Sign Gene Therapy Manufacturing Services Agreement

Agreement includes large-scale cGMP manufacturing service for clinical trials, process characterization, and validation services.

OBiO Technology Corp., a provider of gene and cell therapy-focused biotechnology, entered into a strategic commercial manufacturing collaboration with Chinagene, a developer of clinical genetic diagnosis, and gene therapy drugs. Under the agreement, OBiO will provide contract development and manufacturing services to Chinagene for their gene therapy products, including large-scale cGMP manufacturing service for clinical trials, process characterization and validation services, product formula...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters